RxDoctor Payments DataLook up a doctor →

Richard Price, MD

Psychiatry · Monsey, NYNPI 1104891407

Payments from drug & device makers

$1,712,632in general payments, 2019–2025

Across 2,387 payments — averaging $717.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$375K
  • AbbVie$307K
  • Alkermes, Inc.$297K
  • Axsome Therapeutics, Inc.$148K
  • Otsuka America Pharmaceutical, Inc.$146K
  • E.r. Squibb & Sons, L.L.C.$143K
  • plus $297K from 32 others
$22,850in research payments, 2019–2025

Across 5 payments — averaging $4570.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$23K

What the payments were for

  • Consulting fees$126,0347%
  • Speaking & faculty fees$1,333,68078%
  • Travel & lodging$200,66012%
  • Food & beverage$52,0533%
  • Education$2040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,712,632 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$27,118
Medicare patients
53
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate164$259,346
VraylarCariprazine Hcl107$156,257
AplenzinBupropion Hbr38$125,938
Abilify MaintenaAripiprazole19$51,167
AuvelityDextromethorphan Hbr/Bupropion50$49,751
Lamictal XrLamotrigine12$29,519
QuviviqDaridorexant Hcl62$29,090
CaplytaLumateperone Tosylate17$26,332
Lamictal OdtLamotrigine25$20,787
Lurasidone Hcl23$19,867
RexultiBrexpiprazole12$17,465
NuvigilArmodafinil15$16,137
TrintellixVortioxetine Hydrobromide31$14,223
VyvanseLisdexamfetamine Dimesylate46$10,979
SunosiSolriamfetol Hcl12$9,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$296,737$259,346164 claims
AbbVieVraylar$306,938$156,257107 claims
Bausch Health US, LLCAplenzin$696$125,93838 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$146,006$68,63231 claims
Axsome Therapeutics, Inc.Auvelity, Sunosi$148,077$59,69862 claims
Idorsia Pharmaceuticals US IncQuviviq$13,429$29,09062 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$44,611$26,33217 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$275$25,20277 claims
Ironshore Pharmaceuticals Inc.Jornay Pm$742$6,33315 claims
Johnson & JohnsonConcerta$374,832$6,16714 claims
MerckBelsomra$90$5,41513 claims
Eisai Inc.Dayvigo$209$4,09613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Monsey

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →